Guselkumab, IL-17 Inhibitors Show Comparable Benefits for Psoriatic Arthritis Patients
Psoriatic arthritis (PsA) significantly impacts patients’ lives, affecting daily activities, emotional well-being, and physical health. While targeted biologics have proven efficacy in clinical trials, comparative real-world data remain scarce. The 6-month interim results from the ongoing PsABIOnd observational study presented at the American College of Rheumatology (ACR) Convergence 2024, held November 14-19 in Washington, DC, offer fresh insights into the patient-reported impact of guselkumab and IL-17 inhibitors in managing PsA.
The study analyzed 619 PsA patients, including 323 on guselkumab and 296 on IL-17 inhibitors, who provided baseline and 6-month follow-up data for the PsA Impact of Disease-12 (PsAID-12) tool. This tool assesses 12 domains such as pain, fatigue, skin problems, and depression, with higher scores indicating worse outcomes.
At the 6-month mark, both the guselkumab and IL-17 inhibitor groups showed clinically meaningful improvements in PsAID-12 total scores. The mean change was -1.5 for guselkumab and -1.6 for IL-17 inhibitors, with no significant differences observed between the cohorts after propensity score adjustments. Around half of the patients in both groups (53% for guselkumab, 48% for IL-17 inhibitors) achieved minimal clinically important improvement (MCII) in their total PsAID-12 scores.
Subdomain analyses revealed similar patterns of improvement. Patients reported the greatest reductions in skin problems and discomfort, with smaller but notable improvements in areas such as depression.
These findings highlight the comparable efficacy of guselkumab and IL-17 inhibitors in reducing the perceived burden of PsA, reinforcing their roles as effective therapeutic options. For clinicians and patients, this data supports a shared decision-making approach to selecting treatment, tailored to individual preferences and needs.
Reference
Siebert S, Sharaf M, Selmi C, Rahman P, et al. Guselkumab and IL-17 inhibitors improve patient-perceived impact of psoriatic arthritis similarly: 6-month interim results of the PsABIOnd observational cohort study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). Accessed January 6, 2025.
